These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 19523013)

  • 1. Safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple doses of lecozotan in healthy young and elderly subjects.
    Patat A; Parks V; Raje S; Plotka A; Chassard D; Le Coz F
    Br J Clin Pharmacol; 2009 Mar; 67(3):299-308. PubMed ID: 19523013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A positron emission tomography study to assess binding of lecozotan, a novel 5-hydroxytryptamine-1A silent antagonist, to brain 5-HT1A receptors in healthy young and elderly subjects, and in patients with Alzheimer's disease.
    Raje S; Patat AA; Parks V; Schechter L; Plotka A; Paul J; Langstrom B
    Clin Pharmacol Ther; 2008 Jan; 83(1):86-96. PubMed ID: 17507923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humans.
    Rosenberg G; Angel I; Kozak A
    Br J Clin Pharmacol; 2005 Jul; 60(1):7-16. PubMed ID: 15963088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, Tolerability and Pharmacokinetics of the Serotonin 5-HT6 Receptor Antagonist, SUVN-502, in Healthy Young Adults and Elderly Subjects.
    Nirogi R; Mudigonda K; Bhyrapuneni G; Muddana NR; Goyal VK; Pandey SK; Palacharla RC
    Clin Drug Investig; 2018 May; 38(5):401-415. PubMed ID: 29380267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, Tolerability, Pharmacokinetics and Quantitative Electroencephalography Assessment of ACD856, a Novel Positive Allosteric Modulator of Trk-Receptors Following Multiple Doses in Healthy Subjects.
    Önnestam K; Nilsson B; Rother M; Rein-Hedin E; Bylund J; Anderer P; Kemethofer M; Halldin MM; Sandin J; Segerdahl M
    J Prev Alzheimers Dis; 2023; 10(4):778-789. PubMed ID: 37874100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant blockade of 5-HT(1A) receptor and 5-HT transporter: use of the Hunter Serotonin toxicity criteria in a clinical pharmacology study.
    Parks V; Philipp AW; Raje S; Plotka A; Schechter LE; Connell J; Chalon S
    Eur Neuropsychopharmacol; 2012 Feb; 22(2):92-9. PubMed ID: 21733663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study.
    Derks M; Anzures-Cabrera J; Turnbull L; Phelan M
    Clin Drug Investig; 2011; 31(5):325-35. PubMed ID: 21366361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties.
    Schechter LE; Smith DL; Rosenzweig-Lipson S; Sukoff SJ; Dawson LA; Marquis K; Jones D; Piesla M; Andree T; Nawoschik S; Harder JA; Womack MD; Buccafusco J; Terry AV; Hoebel B; Rada P; Kelly M; Abou-Gharbia M; Barrett JE; Childers W
    J Pharmacol Exp Ther; 2005 Sep; 314(3):1274-89. PubMed ID: 15951399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, Tolerability and Pharmacokinetics of Icapamespib, a Selective Epichaperome Inhibitor, in Healthy Adults.
    Silverman MH; Duggan S; Bardelli G; Sadler B; Key C; Medlock M; Reynolds L; Wallner B
    J Prev Alzheimers Dis; 2022; 9(4):635-645. PubMed ID: 36281667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
    Hey JA; Yu JY; Versavel M; Abushakra S; Kocis P; Power A; Kaplan PL; Amedio J; Tolar M
    Clin Pharmacokinet; 2018 Mar; 57(3):315-333. PubMed ID: 29063518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacokinetics and tolerability of dotarizine in healthy subjects after single and multiple oral administration.
    Farré M; Roset PN; Llorente M; Márquez M; Albet C; Pérez JA; Herrero E; Ortíz JA
    Methods Find Exp Clin Pharmacol; 1997 Jun; 19(5):343-50. PubMed ID: 9379783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial.
    Leber A; Hontecillas R; Zoccoli-Rodriguez V; Colombel JF; Chauhan J; Ehrich M; Farinola N; Bassaganya-Riera J
    Inflamm Bowel Dis; 2020 Mar; 26(4):643-652. PubMed ID: 31077582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug.
    Richard M; Kaufmann P; Ort M; Kornberger R; Dingemanse J
    CNS Drugs; 2020 Mar; 34(3):311-323. PubMed ID: 31994022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
    Vaughan D; Speed J; Medve R; Andrews JS
    Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers.
    Leong FJ; Zhao R; Zeng S; Magnusson B; Diagana TT; Pertel P
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6437-43. PubMed ID: 25136017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
    Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, pharmacokinetics and exploratory pro-cognitive effects of HTL0018318, a selective M
    Bakker C; Tasker T; Liptrot J; Hart EP; Klaassen ES; Doll RJ; Brown GA; Brown A; Congreve M; Weir M; Marshall FH; Cross DM; Groeneveld GJ; Nathan PJ
    Alzheimers Res Ther; 2021 Apr; 13(1):87. PubMed ID: 33883008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
    Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
    Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical studies of the advanced glycation end-product (AGE)-breaker TRC4186: safety, tolerability and pharmacokinetics in healthy subjects.
    Chandra KP; Shiwalkar A; Kotecha J; Thakkar P; Srivastava A; Chauthaiwale V; Sharma SK; Cross MR; Dutt C
    Clin Drug Investig; 2009; 29(9):559-75. PubMed ID: 19663519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist.
    van Giersbergen PL; Dingemanse J
    Eur J Clin Pharmacol; 2007 Feb; 63(2):151-8. PubMed ID: 16636870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.